Patents Assigned to Senex Biotechnology, Inc.
-
Patent number: 11572369Abstract: Disclosed herein are bicyclic pyridines, such as thienopyridine, pyrrolopyridine, furopyridine compounds, and methods for treating cancers.Type: GrantFiled: February 3, 2020Date of Patent: February 7, 2023Assignees: UNIVERSITY OF SOUTH CAROLINA, SENEX BIOTECHNOLOGY, INC.Inventors: Igor B. Roninson, Mengqian Chen, Jing Li, Jiaxin Liang, Li Zhang, Campbell McInnes
-
Publication number: 20210322651Abstract: The invention provides methods for suppressing neointimal formation resulting from vascular surgery, comprising administering to a patient having vascular surgery one or more inhibitors of CDK8/19.Type: ApplicationFiled: December 18, 2015Publication date: October 21, 2021Applicant: Senex Biotechnology, Inc.Inventors: Igor B. Roninson, Taixing Cui
-
Publication number: 20210276956Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.Type: ApplicationFiled: May 25, 2021Publication date: September 9, 2021Applicants: University of South Carolina, Senex Biotechnology, Inc.Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
-
Patent number: 11014906Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted quinoline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.Type: GrantFiled: August 21, 2019Date of Patent: May 25, 2021Assignees: University of South Carolina, Senex Biotechnology, Inc.Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
-
Patent number: 10993945Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient.Type: GrantFiled: March 9, 2016Date of Patent: May 4, 2021Assignee: SENEX BIOTECHNOLOGY, INC.Inventors: Igor B Roninson, Donald C Porter
-
Patent number: 10584369Abstract: The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such overexpression in a concentration-dependent manner, thereby allowing the determination of the activity of the compound in inhibiting its target protein in live cells.Type: GrantFiled: January 13, 2014Date of Patent: March 10, 2020Assignee: Senex Biotechnology, Inc.Inventors: Igor B Roninson, Donald C Porter, Serena Altilia
-
Publication number: 20200062728Abstract: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.Type: ApplicationFiled: August 21, 2019Publication date: February 27, 2020Applicants: University of South Carolina, Senex Biotechnology, Inc.Inventors: Igor Roninson, Campbell McInnes, Mengqian Chen, Li Zhang, Jing Li
-
Publication number: 20200048208Abstract: The invention provides a method for treating a disease or disorder in a mammal which is caused by induced NFkB transcriptional activity in cells of the mammal, the method comprising administering to the mammal a compound that specifically inhibits one or more of CDK8 and CDK19.Type: ApplicationFiled: August 23, 2019Publication date: February 13, 2020Applicant: Senex Biotechnology, Inc.Inventors: Donald C. PORTER, Igor B. RONINSON
-
Publication number: 20170115308Abstract: The invention provides a method for determining the efficacy of a small molecule for inhibiting cyclin-dependent kinase 8 (CDK8) and/or cyclin-dependent kinase 19 (CDK19), using STAT1 phosphorylation as a PD marker.Type: ApplicationFiled: December 1, 2015Publication date: April 27, 2017Applicant: SENEX BIOTECHNOLOGY, INC.Inventor: Igor B. Roninson
-
Publication number: 20170071942Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient.Type: ApplicationFiled: March 9, 2016Publication date: March 16, 2017Applicant: SENEX BIOTECHNOLOGY INCInventors: IGOR B. RONINSON, DONALD C PORTER
-
Patent number: 9409873Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.Type: GrantFiled: June 21, 2013Date of Patent: August 9, 2016Assignee: SENEX BIOTECHNOLOGY INC.Inventors: Donald C Porter, Igor B Roninson, Mark P Wentland
-
Patent number: 9321737Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient.Type: GrantFiled: February 1, 2013Date of Patent: April 26, 2016Assignee: SENEX BIOTECHNOLOGY INCInventors: Igor B Roninson, Donald C Porter, Mark P Wentland
-
Publication number: 20160000787Abstract: The invention provides a selective inhibitor of CDK8/19 for use in a method of treating a patient having estrogen receptor positive (ER+) breast cancer, including breast cancer that is resistant to antiestrogen therapy. In some embodiments, the selective inhibitor of CDK8/19 is administered in combination with antiestrogen therapy. In some embodiments, the selective inhibitor of CDK8/19 is administered to ER+HER2+ breast cancer patients in combination with HER2-targeting drugs.Type: ApplicationFiled: February 26, 2014Publication date: January 7, 2016Applicant: SENEX BIOTECHNOLOGY, INC.Inventors: Eugenia Broude, Igor B Roninson
-
Publication number: 20140199708Abstract: The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such overexpression in a concentration-dependent manner, thereby allowing the determination of the activity of the compound in inhibiting its target protein in live cells.Type: ApplicationFiled: January 13, 2014Publication date: July 17, 2014Applicant: SENEX BIOTECHNOLOGY INC.Inventors: Igor B. Roninson, Donald C. Porter, Serena Altilia
-
Publication number: 20140038958Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient.Type: ApplicationFiled: February 1, 2013Publication date: February 6, 2014Applicant: SENEX BIOTECHNOLOGY INC.Inventors: Igor B. Ronnison, Donald C. Porter, Mark P. Wentland
-
Publication number: 20120071477Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.Type: ApplicationFiled: November 30, 2010Publication date: March 22, 2012Applicant: Senex Biotechnology, Inc.Inventors: Donald C. Porter, Igor B. Roninson, Mark P. Wentland